93 related articles for article (PubMed ID: 7982368)
1. Salbutamol in treatment of bronchial asthma--comparison of controlled release tablet with standard tablet.
Wang CR; Yeh TS; Chuang CY; Chen CY
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1993 Aug; 26(3):132-7. PubMed ID: 7982368
[TBL] [Abstract][Full Text] [Related]
2. [Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily].
Ringbaek TJ; Søes-Petersen U; Christensen M; Iversen ET; Rasmussen FV
Ugeskr Laeger; 1996 Jul; 158(27):3940-3. PubMed ID: 8701511
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya.
Gathua SN; Aluoch JA
East Afr Med J; 1990 Dec; 67(12):850-5. PubMed ID: 2083519
[TBL] [Abstract][Full Text] [Related]
4. A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma.
Beskow R; Ericsson CH; Grönneberg R; Sjögren I; Skedinger M
Eur J Respir Dis; 1984 Oct; 65(7):509-11. PubMed ID: 6386512
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease.
Maesen FP; Smeets JJ
Eur J Clin Pharmacol; 1986; 31(4):431-6. PubMed ID: 3816923
[TBL] [Abstract][Full Text] [Related]
6. Controlled release salbutamol tablets versus sustained release theophylline tablets in the control of reversible obstructive airways disease.
Vyse T; Cochrane GM
J Int Med Res; 1989; 17(1):93-8. PubMed ID: 2651178
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma.
Lipworth BJ; Clark RA; Dhillon DP; Moreland TA; Struthers AD; Clark GA; McDevitt DG
Eur J Clin Pharmacol; 1989; 37(6):567-71. PubMed ID: 2693116
[TBL] [Abstract][Full Text] [Related]
8. Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Skoner DP; Boltansky H; Kobayashi RH; Pearlman DS; Shapiro G; Harrison JE; Trochelmann LM; Lorber RR
Ann Allergy Asthma Immunol; 1996 May; 76(5):462-8. PubMed ID: 8630721
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Lin Q; Liu QH; Bao YX
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):462-5. PubMed ID: 23791063
[TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks.
Kokturk N; Turktas H; Kara P; Mullaoglu S; Yilmaz F; Karamercan A
Pulm Pharmacol Ther; 2005; 18(6):416-21. PubMed ID: 15953743
[TBL] [Abstract][Full Text] [Related]
11. [Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
Sprogøe-Jakobsen U; Viktrup L; Davidsen O; Viskum K
Ugeskr Laeger; 1992 Nov; 154(47):3325-8. PubMed ID: 1361083
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.
Najafizadeh K; Sohrab Pour H; Ghadyanee M; Shiehmorteza M; Jamali M; Majdzadeh S
Emerg Med J; 2007 May; 24(5):317-21. PubMed ID: 17452695
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
Martin RJ; Kraft M; Beaucher WN; Kiechel F; Sublett JL; LaVallee N; Shilstone J
Ann Allergy Asthma Immunol; 1999 Aug; 83(2):121-6. PubMed ID: 10480584
[TBL] [Abstract][Full Text] [Related]
14. A study with cumulative doses of formoterol and salbutamol in children with asthma.
Foucard T; Lönnerholm G
Eur Respir J; 1991 Nov; 4(10):1174-7. PubMed ID: 1687130
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.
Lipworth BJ; Clark RA; Dhillon DP; Palmer JB; McDevitt DG
Eur J Clin Pharmacol; 1990; 39(3):281-5. PubMed ID: 2257867
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of bronchial asthma in winter using controlled-release salbutamol].
Rico FG; Espinoza JL; Montero P; Espinoza F; Mancilla A; Sánchez A; Villanueva CM
Rev Alerg Mex (1987); 1990; 37(5):165-71. PubMed ID: 2094946
[TBL] [Abstract][Full Text] [Related]
17. A comparison of slow-release salbutamol with slow-release aminophylline in nocturnal asthma.
Milledge JS; Morris J
J Int Med Res; 1979; 7 Suppl 1():106-10. PubMed ID: 35430
[No Abstract] [Full Text] [Related]
18. The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma.
Haahtela T; Alanko K; Muittari A; Lahdensuo A; Sahlström K; Vilkka V
Ann Allergy; 1989 Jan; 62(1):63-6. PubMed ID: 2912326
[TBL] [Abstract][Full Text] [Related]
19. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels.
Rodrigo G; Rodrigo C
Am J Emerg Med; 1996 Mar; 14(2):144-50. PubMed ID: 8924135
[TBL] [Abstract][Full Text] [Related]
20. Salbutamol: tablets, inhalational powder, or nebuliser?
Grimwood K; Johnson-Barrett JJ; Taylor B
Br Med J (Clin Res Ed); 1981 Jan; 282(6258):105-6. PubMed ID: 6779890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
